The team of researcher Qin Wenxin of Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, the team of Zhai Bo, chief physician of the Department of Interventional Oncology, and the team of Zhou Weiping, chief physician of Shanghai Oriental Hepatobiliary Surgery Hospital, and Academician Rene Bernards of the Netherlands Cancer Institute found that For patients with advanced liver cancer who are not effective in lenvatinib treatment, combined treatment with gefitinib can effectively inhibit the progression of liver cancer
According to Qin Wenxin, the co-corresponding author of the paper, according to the latest global tumor statistics released by the World Health Organization, the number of liver cancer cases in China accounted for 45.
Lenvatinib is an oral multi-kinase target inhibitor that can inhibit kinases such as vascular endothelial growth factor receptor and fibroblast growth factor receptor
To this end, the researchers used a clustered regularly spaced short palindrome repeat sequence and its related protein 9 nuclease (CRISPR-Cas9) gene editing high-throughput functional screening system, and found that one of the receptor tyrosine kinases was knocked out of epidermal growth.
Researchers have found that although lenvatinib can block the tumor-promoting signal pathway of fibroblast growth factor receptor (FGFR, an important member of the receptor tyrosine kinase family) in liver cancer cells, it is not enough to kill Dead liver cancer cells, liver cancer cells can "break a new path" by activating another receptor tyrosine kinase, epidermal growth factor receptor EGFR, to provide enough signals to promote cancer cell proliferation and survive
At the same time, the researchers also found that using lenvatinib, the use of genetic modification technology to further knock out the epidermal growth factor receptor EGFR can effectively kill liver cancer cells
"In this study, the researchers announced the first batch of 12 cases of liver cancer patients with high expression of EGFR who had failed lenvatinib treatment after combined with gefitinib.
Related paper information: https://doi.
https://doi.
org/10.
1038/s41586-021-03741-7
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
